PAX2, PAX8, and PR are correlated with ovarian seromucinous borderline tumor with endometriosis

[1] Rutgers JL(1988)Ovarian mullerian mucinous papillary cystadenomas of borderline malignancy. A clinicopathologic analysis Cancer 61 340-348

[2] Scully RE(2016)Seromucinous tumors of the ovary. What’s in a name? Int J Gynecol Pathol 35 78-81

[3] Kurman RJ(2002)Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas Am J Surg Pathol 26 1529-1541

[4] Shih IM(2006)Ovarian atypical proliferative (borderline) mucinous tumors; gastrointestinal and seromucinous (endocervical-like) types are immunophenotypically distinctive Int J Gynecol Pathol 25 83-89

[5] Shappell HW(2016)Mullerian mucinous/mixed epithelial (Seromucinous) ovarian tumors AJSP 21 206-213

[6] Riopel MA(2020)Staging procedures fail to benefit women with borderline ovarian tumours who want to preserve fertility: a retrospective analysis of 448 cases BMC Cancer 20 769-332

[7] Smith Sehdev AE(2021)Oncologic and reproductive outcomes of borderline ovarian tumors in Indian population Gynecol Oncol Rep 36 100756-1847

[8] Ronnett BM(2010)PAX-2 expression in non-neoplastic, primary neoplastic, and metastatic neoplastic tissue: A comprehensive immunohistochemical study Appl Immunohistochem Mol Morphol 18 323-764

[9] Kurman RJ(2011)PAX2 and PAX8 expression in primary and metastatic mullerian epithelial tumors: a comprehensive comparison Am J Surg Pathol 35 1837-1251

[10] Vang R(2011)PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: a comprehensive immunohistochemical study Mod Pathol 24 751-6105

[1] Rutgers JL(1988)Ovarian mullerian mucinous papillary cystadenomas of borderline malignancy. A clinicopathologic analysis Cancer 61 340-348

[2] Scully RE(2016)Seromucinous tumors of the ovary. What’s in a name? Int J Gynecol Pathol 35 78-81

[3] Kurman RJ(2002)Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas Am J Surg Pathol 26 1529-1541

[4] Shih IM(2006)Ovarian atypical proliferative (borderline) mucinous tumors; gastrointestinal and seromucinous (endocervical-like) types are immunophenotypically distinctive Int J Gynecol Pathol 25 83-89

[5] Shappell HW(2016)Mullerian mucinous/mixed epithelial (Seromucinous) ovarian tumors AJSP 21 206-213

[6] Riopel MA(2020)Staging procedures fail to benefit women with borderline ovarian tumours who want to preserve fertility: a retrospective analysis of 448 cases BMC Cancer 20 769-332

[7] Smith Sehdev AE(2021)Oncologic and reproductive outcomes of borderline ovarian tumors in Indian population Gynecol Oncol Rep 36 100756-1847

[8] Ronnett BM(2010)PAX-2 expression in non-neoplastic, primary neoplastic, and metastatic neoplastic tissue: A comprehensive immunohistochemical study Appl Immunohistochem Mol Morphol 18 323-764

[9] Kurman RJ(2011)PAX2 and PAX8 expression in primary and metastatic mullerian epithelial tumors: a comprehensive comparison Am J Surg Pathol 35 1837-1251

[10] Vang R(2011)PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: a comprehensive immunohistochemical study Mod Pathol 24 751-6105